possibilities/probabilities, page-2

Hi cmk,

"I would be intently interested in understanding abdm's understanding of the potential at this corner of the market!?!"

Imho, I think we may both see retirement before pharmaceutical microneedle developments become a commercially reality for OBJ, but that's not to suggest that I think it is many years away, but rather that retirement will come earlier :)

Sent: Thursday, 18 August 2011 10:33 PM
To: Glyn Denison

From recent media coverage highlighting the work of scientist Prof Mark Kendall from the University of Queensland in relation to the NanoPatch I’ve also noted Prof Michael Roberts has been cited in many published papers as a co-author. To my understanding (and as stated on the University of Queensland’s website) OBJ have been providing research funding to Prof Roberts from 2008-2011. Are you able to confirm if OBJ might be one of the International Alliance partners for the NanoPatch Vaccine Development Program?

From: Glyn Denison
Sent: Friday, August 19, 2011 1:44 PM

Yes, we are encouraged with micro-needle developments but with so much of what we have on at the moment, we are keeping this form of research at a lower ebb today but not dismissive of it as well.

Yes, we are encouraged... hmmm? Not sure if you would interpret the beginning of his response to my question there, as an admission, but I'll leave that up to you, cmk ;)

It should also be noted that at the time of my email to Mr Denison on 19/08/2011 OBJ Limited had never indicated being involved with any R&D work relating to microneedles, however research on the company did indicate a relationship to 'intra-dermal' R&D work.

4D Half Yearly - Reporting for the period 30/06/2011 - 31/12/2011

The company's work with microneedles was also expanded during the period with the receipt of the first positive results of enhanced delivery when used in conjunction with microneedles. This has led to the development of new Intellectual Property and a number of new product forms that utilize this combination of technologies.

Shareholder Update - 26/04/2014

The Company has been working with the University of Queensland and in particular Dr Tarl Prow in the development of enhancing micro-needle performance with the addition of OBJ’s ETP magnetic technology. OBJ’s ETP technology, when integrated into a traditional micro-needle delivery system, showed substantially greater drug delivery than micro-needles alone. The resulting technology was the subject of a recent patent application and the results of that work were presented at the PPP Drug delivery Conference in France early in the month by OBJ Director, Dr Chris Quirk.

Shareholder Update - 15/08/2012

The Company’s work with the University of Queensland in
enhancing the passage of drug from the skin into the viable epidermis following micro-needle application continues. The previous encouraging results by the University are now being developed into more commercially focused opportunities.

Even though having a paper (article or letter) published in any Nature publication is usually considered to be very prestigious, and are only sent for review if it is decided that they are sufficiently ground-breaking in a particular field, it's apparent that managements view of its 'lower ebb' research being published by the world's most prestigious scientific publishing group does not even warrant any mention in a company announcement.

While one can appreciate the successful commercialization of this microneedle product platform incorporating OBJ's ETP technology will still be a number of years away, and OBJ collaborating researchers, Profs. Michael Roberts, Ian Frazer, and Tarl Prow are all cited as co-authors on Mark Kendall's NanoPatch papers, OBJ in response to s/holder enquiries have continued to deny any connection.

"OBJ has unique transdermal delivery technologies that, if proven in clinical trials, have the potential to provide significant public health benefits and improve the availability of vaccines to developing countries" ~ Prof Ian Frazer.

Imho, Pman will have his private island long before OBJ and/or Kendall's Vaxxas group ever get to commercialize these disruptive technology offerings...